Iwilfin (eflornithine) — United Healthcare

Initial criteria

• Diagnosis of high-risk neuroblastoma (HRNB)
• Patient has shown at least a partial response to prior multiagent, multimodality therapy
• Prior therapy included anti-GD2 immunotherapy (e.g., Danyelza (naxitamabgqgk), Unituxin (dinutuximab))

Reauthorization criteria

• Patient does not show evidence of progressive disease while on Iwilfin therapy

Approval duration

12 months